Treace Medical Concepts Announces Peer-Reviewed Publication Of The 4-Year Interim Results From Its ALIGN3D Multicenter Prospective Study Demonstrating Clinical And Radiographic Outcomes Of The Lapiplasty Procedure In The Journal Of Foot & Ankle Surgery
Benzinga Newsdesk 1 year ago
BiotechNewsGeneral
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the peer-reviewed publication of the four-year interim results from its ALIGN3D&trad
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the peer-reviewed publication of the four-year interim results from its ALIGN3D™ multicenter prospective study demonstrating positive clinical and radiographic outcomes of the Lapiplasty® Procedure in the Journal of Foot & Ankle Surgery.
The published results entitled, "Four-Year Outcomes Following Triplanar Tarsometatarsal Arthrodesis with Early Weightbearing for Hallux Valgus: A Multicenter Prospective Study" include interim data on 139 of 173 study patients treated with at least four years of follow-up from Lapiplasty® in the prospective, five-year, multicenter ALIGN3D™ clinical study. The data showed:
- Early return to protected weight bearing at an average of 7.7 days and return to athletic shoes at 6.5 weeks;
- Low radiographic recurrence rates of 0.8% using HVA>20° and 8.4% using HVA>15° at 48 months; and
- Continued significant improvement in pain and patient-reported outcome scores (VAS, MOxFQ and PROMIS), including an 81% improvement in pain and 89% improvement in walking/standing on the MOxFQ scoring system through 48 months.